TxCell, a French biotechnology company developing personalised cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, has added Olivier Danos to its Scientific Advisory Board (SAB).
Danos is Senior Vice President of Cell and Gene Therapy at Biogen and an expert in the field of gene therapy for haematological and neurological diseases.
'Dr Olivier Danos has pioneered technologies of central importance in the field of gene therapy and genome editing,' said Arnaud Foussat, Chief Scientific Officer of TxCell.
'He is another significant addition to our SAB, which already includes leading experts in immunology, T-cell biology and chimeric antigen receptors.
'These include Professor Zelig Eshhar as Chairman, who was recently awarded the Novartis Prize for Clinical Immunology.'
Danos has led Biogen’s gene therapy research group since 2014. Prior this, he was Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation, at Kadmon Pharmaceuticals.
Before this, Danos was the Director of the Gene Therapy Consortium at University College, London, and led a gene therapy research team at the Necker Hospital – Enfants Malades in Paris.
His other previous appointments include Scientific Director of Généthon and Senior Research Director with the CNRS in France.
TxCell created its SAB in March with the appointment of the first three members: Professor Zelig Eshhar (Chairman), Professor of Immunology, Chair of Immunology Research, Weizmann Institute of Science, Rehovot, Israel; Professor Chiara Bonini, Head of Unit, Experimental Haematology, San Raffaele Hopital, Milan, Italy; and Dr Bernard Malissen, Research Director, Immunology, Centre of Marseille-Luminy, Marseille, France.